BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag HB, Christie IC, Puenpatom A, Castillo D, Kanwal F, Kramer JR. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019;49:1442-1447. [PMID: 30932218 DOI: 10.1111/apt.15240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
2 Rodríguez-Tajes S, Pocurull A, Castillo J, Casanova G, Vega L, Lens S, Mariño Z, Londoño MC, Forner A, Torres F, Forns X. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J Hepatol 2020;73:1360-7. [PMID: 32697948 DOI: 10.1016/j.jhep.2020.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Zaimi Y, Ayari M, Cherifi W, Letaief Ksontini F, Ayadi S, Bel Hadj Mabrouk E, Jrad M. Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C. BMJ Open Gastroenterol 2021;8:e000721. [PMID: 34400439 DOI: 10.1136/bmjgast-2021-000721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Yu ML. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol 2020;115:1226-35. [PMID: 32221162 DOI: 10.14309/ajg.0000000000000606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
5 Liu CH, Kao JH. Reply to: "Sofosbuvir and the risk of kidney dysfunction". J Hepatol 2021;74:257-8. [PMID: 33071008 DOI: 10.1016/j.jhep.2020.09.028] [Reference Citation Analysis]
6 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gonzalez HC, Gordon SC. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? Gastroenterol Clin North Am 2020;49:301-14. [PMID: 32389364 DOI: 10.1016/j.gtc.2020.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Carole S, Elena L, Bénédicte LV, Abdoul-Aziz D, Dominique DT, Weil DR, Agnès D, Pascal L. Acute Myeloid Leukaemia following Direct Acting Antiviral drugs in HCV-infected patients: a 10 years' retrospective single-center study. Clin Res Hepatol Gastroenterol 2022;:102000. [PMID: 35933093 DOI: 10.1016/j.clinre.2022.102000] [Reference Citation Analysis]
9 Nevola R, Rinaldi L, Zeni L, Romano C, Marrone A, Galiero R, Pafundi PC, Acierno C, Vetrano E, Adinolfi LE. Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Rev Gastroenterol Hepatol 2021;15:643-56. [PMID: 33445990 DOI: 10.1080/17474124.2021.1877136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dammacco F, Lauletta G, Vacca A. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clin Exp Med. [DOI: 10.1007/s10238-022-00808-1] [Reference Citation Analysis]
11 Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020. Kaohsiung J Med Sci 2021;37:7-11. [PMID: 33337581 DOI: 10.1002/kjm2.12345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sakai H, Miwa T, Ikoma Y, Hanai T, Nakamura N, Imai K, Kitagawa J, Shirakami Y, Kanemura N, Suetsugu A, Takai K, Shiraki M, Shimizu M. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review. Mol Clin Oncol 2020;13:1. [PMID: 32754315 DOI: 10.3892/mco.2020.2071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
14 Wang W, Lo Re V 3rd, Guo Y, Xiao H, Brown J, Park H. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US. Aliment Pharmacol Ther 2020;52:1592-602. [PMID: 32931606 DOI: 10.1111/apt.16081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]
16 Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Stella Franzè M, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int 2021;41:2059-67. [PMID: 33894103 DOI: 10.1111/liv.14905] [Reference Citation Analysis]
17 Nagao Y. The role of dentists in controlling hepatocellular carcinoma in Japan (Review). Exp Ther Med 2021;21:113. [PMID: 33335576 DOI: 10.3892/etm.2020.9545] [Reference Citation Analysis]
18 Masetti C, Lleo A, Colombo M, Colombo M, Aghemo A. Postsustained Virological Response Management in Hepatitis C Patients. Semin Liver Dis 2020;40:233-9. [PMID: 32107758 DOI: 10.1055/s-0040-1702944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cacoub P, Comarmond C, Vieira M, Régnier P, Saadoun D. HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. J Hepatol 2021:S0168-8278(21)02084-5. [PMID: 34600000 DOI: 10.1016/j.jhep.2021.09.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
21 Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. J Hepatol 2019;71:1116-25. [PMID: 31433302 DOI: 10.1016/j.jhep.2019.07.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
22 Adinolfi LE, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, Rinaldi L, Calvaruso V, Pafundi PC, Lombardi R, Staiano L, Di Marco V, Solano A, Marrone A, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A, Sasso FC. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study. Diabetes Obes Metab 2020;22:2408-16. [DOI: 10.1111/dom.14168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
23 Huang CF, Yu ML. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin Mol Hepatol 2020;26:251-60. [PMID: 32188235 DOI: 10.3350/cmh.2020.0018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
24 Liu C, Liu C, Su T, Tseng T, Chen P, Kao J. Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13302] [Reference Citation Analysis]
25 Scelza G, Amato A, Pagano AM, Matteis G, Caruso R, Scelza A, Sisalli L, Biasi S, Marigliano F, Gagliardi M, Martina S, Iandolo A. Effect of hepatitis C antiviral therapy on oral lichen planus and hyposalivation in inmates. Ann Gastroenterol 2022;35:74-9. [PMID: 34987292 DOI: 10.20524/aog.2021.0672] [Reference Citation Analysis]
26 Defrancesco I, Zerbi C, Rattotti S, Merli M, Bruno R, Paulli M, Arcaini L. HCV infection and non-Hodgkin lymphomas: an evolving story. Clin Exp Med 2020;20:321-8. [PMID: 32052244 DOI: 10.1007/s10238-020-00615-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
27 Nagao Y, Tsuji M. Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report. Int J Dent 2021;2021:8925879. [PMID: 34804168 DOI: 10.1155/2021/8925879] [Reference Citation Analysis]
28 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]